CorMedix Inc. | Mutual Funds
Mutual Funds that own CorMedix Inc.
Vanguard Total Stock Market Index Fund
1,253,757
1.28%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
419,187
0.43%
19,400
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
246,421
0.25%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
127,701
0.13%
-50,000
0.02%
12/31/2017
Vanguard Balanced Index Fund
87,680
0.09%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
48,587
0.05%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
23,800
0.02%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
18,963
0.02%
0
0%
09/06/2018
BlackRock Master Extended Market Index Series
7,588
0.01%
0
0%
01/31/2018
Vanguard Invt. Fds. ICVC - US Equity Index Fund
7,395
0.01%
0
0%
06/30/2018
| Address |
400 Connell Drive
Berkeley Heights New Jersey 07921
United States
|
|
Employees
|
- |
| Website |
http://www.cormedix.com |
| Updated |
07/08/2019 |
| CorMedix, Inc. operates as a pharmaceutical and medical device company that seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. |
